ORYN 1064
Alternative Names: ORYN-1064Latest Information Update: 07 Sep 2023
At a glance
- Originator Oryn Therapeutics
- Class Antibacterials; Antimicrobial cationic peptides; Macrocyclic compounds
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 06 Sep 2023 Oryn Therapeutics has patent protection for OrynotidesTM(Oryn therapeutics website, September 2023)
- 06 Sep 2023 Preclinical trials in Bacterial infections in USA (Parenteral) (Oryn Therapeutics pipeline, September 2023)